Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 257

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 257
---
holder approval by March 31, 2025 (subject to an additional three month extension at the discretion of the Board), we will be required to dissolve and liquidate the Trust Account by returning the then remaining funds in such Trust Account to our public stockholders.

After careful consideration, the Iris Board has determined that the Business Combination Proposal, the ParentCo Charter Proposal, the Incentive Plan Proposal and the Adjournment Proposal are fair to and in the best interests of Iris and our stockholders and unanimously recommends that you vote or give instruction to vote “

#### FOR
” the Business Combination Proposal and “

#### FOR
” the other proposals presented in this proxy statement/prospectus. In considering the recommendation of the Iris Board, you should keep in mind that our directors and executive officers may have interests in the Business Combination that are different from or in addition to (and may conflict with) the interests of our stockholders generally. For additional information, see the section entitled “Proposal No. 1 — The Business Combination Proposal — Interests of Certain Persons in the Business Combination.”

#### Recommendation of the Iris Board
<div align='center'>THE IRIS BOARD UNANIMOUSLY RECOMMENDS THAT IRIS STOCKHOLDERS VOTE “FOR” THE BUSINESS COMBINATION PROPOSAL.

123</div>

TABLE OF CONTENTS

#### PROPOSAL NO. 2 — THE NASDAQ PROPOSAL

### Overview
In connection with the Business Combination and the PIPE Equity Investment, Iris is asking Iris’s stockholders to consider and vote upon a proposal to approve for the purposes of complying with the applicable provisions of Nasdaq Listing Rules 5635(a), (b), (c) and (d) the issuance of shares of ParentCo Common Stock, to the extent such issuance would require stockholder approval under Nasdaq Listing Rules 5635(a), (b), (c) and (d).

#### Reasons for the Approval
We are seeking stockholder approval in order to comply with Nasdaq Listing Rules 5635(a), (b), (c), and (d).

Under Nasdaq Listing Rule 5635(a), stockholder approval is required prior to the issuance of securities in connection with the acquisition of another company if such securities are not issued in a public offering and (A) have, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance of common stock (or securities convertible into or exercisable for